Effects of CD4 Cell Counts and Viral Load Testing on Mortality Rates in Patients With HIV Infection Receiving Antiretroviral Treatment: An Observational Cohort Study in Rural Southwest China

作者
Zhiyong Shen,Qiuying Zhu,Zhenzhu Tang,Stephen W. Pan,Heng Zhang,He Jiang,Yi Chen,Guanghua Lan,Hui Qin Xing,Lingjie Liao,Yi Feng,Yuhua Ruan,Yiming Shao
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:63 (1): 108-114 被引量:23
标识
DOI:10.1093/cid/ciw146
摘要

BACKGROUND: Recent studies have suggested that CD4 cell count monitoring has little added value in patients who are virologically suppressed and immunologically stable if viral load (VL) testing is routinely available. These conclusions have not been directly assessed using mortality rate as a study end point in a real-world setting. METHODS: This human immunodeficiency virus (HIV) treatment cohort study from 2008 to 2014 was conducted in Guangxi, China. We used a Cox regression model to analyze associations between the frequency of CD4 cell counts and VL testing and death. RESULTS: Compared with monitoring CD4 cell counts ≥3 times during the first year of antiretroviral therapy (ART) initiation, as currently suggested by the Chinese National Free Antiretroviral Treatment Program, monitoring them less than twice during the first year of ART was significantly associated with death; however, monitoring them twice in that year did not significantly increase mortality rates. Compared with testing VL at least once during the first year of ART, as currently suggested by the National Free Antiretroviral Treatment Program, performing no VL tests in the first year after ART initiation was significantly associated with higher mortality rates. Routine CD4 cell count monitoring did not have an impact on mortality rates among HIV-infected patients with VLs <1000 copies/mL or CD4 cell counts ≥350/μL beyond 12 months after ART initiation. CONCLUSIONS: Our study suggests that CD4 cell counts can be reduced to twice during the first year of ART and be reduced or stopped for patients who have achieved virologic suppression or immunologic stability after 12 months of treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
孤独的凤完成签到,获得积分10
1秒前
2秒前
2秒前
音阙发布了新的文献求助10
2秒前
Sxya发布了新的文献求助30
3秒前
dingyushu完成签到,获得积分10
3秒前
秋风的应助被pinkstar采纳,获得10
3秒前
科研通AI6.3的应助被向星采纳,获得10
4秒前
4秒前
4秒前
dkfsgeicn完成签到,获得积分10
5秒前
情怀的应助被ZYH采纳,获得10
5秒前
6秒前
orixero的应助被Kevin采纳,获得10
6秒前
phoebe发布了新的文献求助10
7秒前
研友_VZG7GZ的应助被香辣牛排采纳,获得10
7秒前
7秒前
8秒前
2dingyushu完成签到,获得积分10
8秒前
852的应助被甜蜜的电灯胆采纳,获得10
8秒前
科研通AI6.3的应助被晚风采纳,获得10
8秒前
melon发布了新的文献求助20
8秒前
疯狂加载ing的应助被hin采纳,获得10
9秒前
wangbw发布了新的文献求助10
10秒前
缺口口发布了新的文献求助80
11秒前
leyi发布了新的文献求助10
11秒前
11秒前
six发布了新的文献求助10
11秒前
12秒前
9dingyushu完成签到,获得积分10
12秒前
12秒前
深情安青的应助被LuoYR@SZU采纳,获得10
13秒前
威武渊思发布了新的文献求助10
15秒前
秋风的应助被www采纳,获得10
16秒前
Ava的应助被无船付采纳,获得10
16秒前
红红发布了新的文献求助10
16秒前
16秒前
mhx1234567890发布了新的文献求助10
17秒前
科烟生发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593